The benefit of donor lymphocyte infusion in the tyrosine kinase inhibitors era in chronic myeloid leukemia post allogeneic hematopoietic cell transplantation.
Study #: CK16-02b
Study Status: Published
Presentation(s)
2018, ASH (Oral)
The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era.
Citation
Schmidt S, Liu Y, Hu Z-H, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ortí G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W.
Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation. 2020, Jun 01: 26(6): 26(6):1137-1143. doi: 10.1016/j.bbmt.2020.02.006. Epub 2020, Feb 14. PMCID:PMC7367282.
PubMed
PMID: 32062061
Abstract